

Home Biosciences announces launch of its first venture, One Biosciences

Home Biosciences, Europe's first biotech venture builder, announced today the launch of its first venture, One Biosciences. The Company is focused on generating precision medicines by leveraging the power of single-cell technologies, backed and supported by Institut Curie and Home Biosciences, and co-founded by Dr. Céline Vallot, a pioneer of single-cell data analysis globally.

Home Biosciences is building a portfolio of high-potential and well-designed transformative technologies and assets to bring them to key value inflexion points in an expedited and capital efficient manner, by leveraging strong operational guidance and drug development expertise as well as funding resources under one roof. Its operating model allows full focus of its ventures on scientific and operational excellence and quality of execution to significantly expedite and de-risk their operational roadmap without the requirement of building dedicated expensive company infrastructure at the earliest stages of scientific developments.

By teaming-up with leading academics and scientists around smart business models and by creating agile dedicated ventures staffed with highly skilled execution teams, while providing adequate financing and support, Home Biosciences allows its teams to fully focus on their objectives in a time and capital efficient manner. This model, dedicated to biotech, is novel in Europe and is designed to develop life-saving therapeutics in a more capital efficient way.

Home Biosciences was co-founded in late 2019 by Magali Richard and David Schilansky, two biotech industry veterans with complementary skills and experiences, ranging from bench science to designing and scaling up companies and to fund raising. They have been joined by Dr. Michel Vellard, Home Biosciences' Chief Scientific Officer, who has contributed to the success of Ultragenyx Pharmaceutical and BioMarin Pharmaceutical, where he was instrumental in translating research assets into ten FDA approved drugs in the field of rare diseases.

Home Biosciences has recently completed its seed funding round, allowing it to assemble its first assets and start the operations of One Biosciences.

“We are proud to have delivered One Biosciences, that we believe has the potential to become a European leader in single-cell generated precision medicines for complex and difficult-to-treat diseases. Our operating model will allow One Biosciences to fully focus on its core computational expertise, embedded in project teams along with clinicians and biologists. The Company will leverage the full spectrum of Home Biosciences’ skills and expertise to achieve its ambitious objectives”. said **Dr. Magali Richard**, co-founder & deputy CEO of Home Biosciences.

“Home Biosciences fills a great need in the European biotech ecosystem. As the first Biotech Venture Builder in Europe, and thanks to its unique value proposition combining financial stability and strong operational guidance, we believe Home Biosciences is poised to create significant value. We are currently building our pipeline of projects, with more to come soon; the creation of One Biosciences shows our ability and our commitment to build tomorrow’s leaders based on cutting edge technologies and ground-breaking science.” said **David Schilansky**, co-founder & CEO of Home Biosciences.

About Home Biosciences’ team

Magali Richard has fifteen years of experience in the field of biotechnology, combining academia and industry. Magali graduated from Ecole Polytechnique and Ecole des Mines de Paris, and holds a PhD in Molecular Biology (Université Pierre & Marie Curie). From 2009 to 2011 she was Scientist at Biomarin, pursuing in the rare diseases space and gaining biotech experience in the United States. Subsequently, Magali spent 6 years at the Boston Consulting Group (2011-2016), member of the Healthcare practice within the Paris office, working with various large pharmaceutical companies on all activities along the value chain, as well as biotech companies and investors around new value creation models for emerging technologies. She then joined the Executive Committee of DBV Technologies as Chief Strategy Officer between 2016 and 2019.

David Schilansky has more than twenty years of professional experience, mainly in the pharmaceutical and biotechnology industry. From 2011 to 2019, he co-headed DBV Technologies, transforming the company from a French research start-up to a unicorn. During this period, he led two IPOs on Euronext and Nasdaq, raising around one billion US dollars in total. David began his career as an investment banker in mergers & acquisitions at Warburg Dillon Read, before joining Technicolor, a CAC40 double-listed company on NYSE and Euronext, as head of financial communication. He then worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group Chief Financial Officer, before moving to DBV. David has been a board member of Lysogene SA, a gene therapy company, since 2016. David graduated from Paris Dauphine and Imperial College (London).

Dr. Michel Vellard has more than 20 years of experience in the pharmaceutical industry and has been part of the beginning, growth and success of several companies. Previously, Michel was Vice President of Research at Ultragenyx Pharmaceutical from 2013 to 2018. Before this, he worked at BioMarin Pharmaceutical Inc., from 1999 as Head of Lysosomal Biology, where he directed research on rare diseases. Prior to BioMarin, Michel did a post-doc training at UCLA, where he focused on cystinosis, a rare lysosomal genetic disease. In 1992, Dr. Vellard completed his Ph.D. in Microbiology at Institut Pasteur and Institut Curie in Paris (France). Michel's work on genetics, molecular biology and particularly on treatments of rare diseases has been recognized by several prestigious awards, numerous patents and more importantly ten FDA commercial approvals, so far.

About One Biosciences

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences. For more information, visit: www.onebiosciences.fr

Contacts

Home Biosciences

David Schilansky & Magali Richard
contact@homebiosciences.com

Presse : ALIZE RP

Caroline Carmagnol & Najette Chaib
caroline@alizerp.com
nchaib@alizerp.com
06 64 18 99 59 / 06 18 38 11 14